Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20250207023
- Term of Validity
- 15 April 2025 - 15 April 2026
- Company's Country
- Germany
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The challenges of dementia call for innovative solutions. A German start-up has taken up the challenge by developing a mobile application for dementia prevention at a university hospital in Lower Saxony. The app features a personalised training programme that uses artificial intelligence and scientifically-based methods, and incorporates game-like elements to boost motivation. The start-up seeks international partners (e. g. nursing homes and hospitals) for clinical studies to enhance the app.
- Full Description
-
The number of people with dementia is steadily increasing worldwide and is predicted to rise further. At present, many of the available treatments are used too late or prove inadequate. Drug treatments are not only expensive, they are often started when the disease is already well advanced. While there are many training programmes that focus on cognitive development, physical aspects have been almost completely ignored in the prevention and treatment of dementia.
The start-up's app addresses this problem with three key goals:
• Exercises and tips for preventing dementia
• Brain training, movement, and coordination
• Personalised training programme and feedback supported by motion tracking (movement recognition)
The app is modelled on memory clinics and complies with the guidelines of the World Health Organisation. The target group includes health-conscious individuals, high-risk patients and people with early-stage dementia.
Key features of the technology: This technology is based on an innovative AI health application for the early stages of dementia. At its core is a trainer that uses neural networks to create personalised training programmes. The patient's movements are monitored and analysed using motion tracking. The system itself - a neural network with AI - is trained to perform detailed movement analysis.
In order to further develop the app and improve its effectiveness in the prevention and treatment of dementia, the start-up is looking for nursing homes and clinics to participate in clinical studies (using Android devices). By working with these institutions, the start-up hopes to gain practical insights and improve the applicability of the app in clinical and care settings, as well as open up international markets. - Advantages and Innovations
-
Using the app always has more benefits than side effects. It can be used at an earlier stage of dementia than other types of treatment. Patients can start training while waiting for a diagnosis.
The start-up is working with a doctor of motivational psychology to encourage patients to train with the app, considering the specific needs of the target group. In addition, the start-up is supported by a clinic for psychiatry and psychotherapy at a university medical centre.
Voice control ensures the accessibility of the app. A high standard of data protection is another advantage of the app: All data is hosted in Germany and the app is GDPR compliant. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
- The company is looking for nursing homes and clinics that ideally use Android tablets to conduct clinical trials and obtain further research results. It would be advantageous if these institutions already have experience in this area. For collaboration, it is important that the partners speak German or English to ensure smooth communication. The app itself can be translated into additional languages if needed (German, English, French, Spanish, and Italian are already available). In addition, the company is interested in working with pharmaceutical companies that offer dementia tests or medications for dementia to clinically research and test the effect of these in combination.
- Type and Size of Partner
- Big company
- R&D Institution
- SME 50 - 249
- Type of partnership
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001002 - Clinical Research, Trials
- 06001016 - Physiology
- 06001014 - Neurology, Brain Research
- 01004001 - Applications for Health
- Market keywords
- 05010002 - Cognitive aid
- 02007016 - Artificial intelligence related software
- 05010003 - Patient rehabilitation & training
- 05007006 - Computer-aided diagnosis and therapy
- 05003001 - Therapeutic services
- Sector Groups Involved
- Health
- Digital
- Targeted countries
- All countries